Yarrow Bioscience, Inc. (NasdaqCM: YARW)
Health Care · Pharmaceuticals · US
$39.25
-7.63% today · +147.0% 1Y
Yarrow Bioscience, Inc. (NasdaqCM: YARW) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $118.97M and employs 10 people.
Over the last twelve months the share price has gained 147.0%, trading between 14.03 and 46.95.
YARW price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $118.97M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -66.82
- Dividend yield
- —
- Beta (5Y)
- 2.08
- 52-week high
- $46.95
- 52-week low
- $14.03
- Avg volume (3M)
- —
- Shares outstanding
- 2.80M
- Employees
- 10
- Next earnings
- —
About Yarrow Bioscience, Inc.
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
- ISIN
- US92941V4077
- Founded
- 2025
- Listed since
- Jul 28, 2026
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.